An interventional study of cholecystectomy and Antispasmodic in Gall Bladder Pain, Hepatobiliary Iminodiacetic Acid and Acalculous Cholecystitis, sponsored by Assiut University. Status unknown. Open to participants aged 12 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-20.
Sponsored by Assiut University · Not applicable, Interventional, and Diagnostic
In this study investigators aim to evaluate gallbladder ejection fraction as a predictor for cholecystectomy.
The flow of bile through the biliary system is a complex process that depends on the hormonal environment, digestive phase, and functional response of the gallbladder and sphincter of Oddi to all of these factors. Biliary dyskinesia is a disorder of some component of biliary part of the digestive system in which bile cannot physically flow in the proper direction through the tubular biliary tract which causes biliary colic as defined by Rome IV criteria.
Functional causes of biliary pain, also referred to as biliary dyskinesia, are biliary hypokinesia , biliary hyperkinesia and sphincter of Oddi dysfunction (SOD). The exact pathology of functional biliary colic is still unknown. Reviewing Literature status, There is still some debate about the best method to establish the diagnosis gallbladder dyskinesia and hyperkinesia and whether or not ejection fraction is an accurate predictor of outcome. Which led to difficult.
Biliary dyskinesia is identified through gallbladder ejection fraction (GBEF), which is calculated as the flow of radioactive tracer that is ejected from the gallbladder. A GBEF of \<35% is considered dyskinesia and a GBEF of \<35% is considered hyperkinesia. Patients considered for CCK-HIDA (cholecystokinin hepatobiliary iminodiacetic acid) are those presenting with functional biliary pain based on the Rome IV criteria. Those who present with atypical pain may not need as HIDA (hepatobiliary iminodiacetic acid) as the presentation may be from other pathology.
266 studies on the registry are indexed under Cholecystitis; 46 are open to participants now.
This study's planned enrollment of 20 is below the median of 86 across 167 interventional studies indexed under Cholecystitis.
Browse Cholecystitis studies →Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Procedure: cholecystectomy · Drug: Antispasmodic
cholecystectomy
Antispasmodic
Rate of quality of life improvment after cholecystectomy according to ROME IV criteria
abdominal pain, nausea and vomiting
Time frame: 6 months
No study locations are listed for this record.
This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University